Active Pharmaceutical Ingredient Watch

April 2002
Chemical Market Reporter;4/8/2002, Vol. 261 Issue 14, p11
Trade Publication
Presents news briefs on the pharmaceutical industry as of April 8, 2002. Details on a patent infringement suit filed by Aventis Pharmaceuticals Inc. against Impax Laboratories Inc.; Notification received by Sanofi-Synthelabo Inc.; Approval received by Sicor Inc. for a generic version of Novartis' Aredia.


Related Articles

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;August 2004, Vol. 3 Issue 8, p4 

    The article provides information about latest developments on cancer medicine from the pharmaceutical industry. Grabbing the headlines this month was the multi million-dollar cancer drug purchase agreement forged between pharmaceutical heavyweights Pfizer Inc. and Sanofi-Synthelabo SA. In an...

  • Sanofi-Synthelabo.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p88 

    Features the Sanofi-Synthelabo, a pharmaceutical manufacturer. Core areas of therapeutic research; Allocated budget for worldwide pharmaceutical research and development; Top-selling pharmaceutical products.

  • Sanofi-Synthelabo closes drug distribution centre.  // Life Science Today;Jun2000, Vol. 1 Issue 3, p4 

    Assesses the closure of drug distribution center by Sanofi-Synthelabo in France. Cause of the closure; Layoff system of the company.

  • Dream ticket to Japan.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p6 

    Reports the plan of French drugmaker Sanofi-Synthelabo to expand its business in Japan.

  • MARKET BRIEFS.  // Chemical Market Reporter;01/29/2001, Vol. 259 Issue 5, p14 

    Presents news briefs from the pharmaceuticals industry as of January 29, 2001. Drug application filed by SkyePharma PLC and Sanofi-Synthelabo for Alfuzosin; Price increase made by Biddle Sawyer for all grade of metolose hydroxypropyl methylcellulose and methyl cellulose; Approval of the...

  • Plavix boom drives on sales.  // European Chemical News;7/26/2004, Vol. 81 Issue 2110, p8 

    Reports on an increase in sales of French pharmaceutical firm Sanofi-Synthélabo in the second quarter of 2004. Status of the company's Plavix anticoagulant product in the U.S. prescription drugs market; Total revenues generated from Plavix sales; Information on other high-selling drugs from...

  • Novartis and Teva Lead in Generics.  // Chemical Market Reporter;10/27/2003, Vol. 264 Issue 14, p6 

    Reports that Novartis claims to share the top spot with Teva Pharmaceutical Industries of Israel in the generic drugs market. Total sales in generic drugs posted by Novartis in the third quarter of 2003.

  • New indications.  // Formulary;Sep2006, Vol. 41 Issue 9, p422 

    The article evaluates the Plavix Clopidogrel tablets which is used to prevent strokes and heart attacks in patients from Sanofi-Synthelabo SA / Bristol-Myers Squibb Co., and the Famvir Famiciclovir tablets from Novartis AG which is an antiviral approved for one-day treatment of genital herpes.

  • Aventis Further Bolsters Defense Against Sanofi.  // Chemical Market Reporter;4/12/2004, Vol. 265 Issue 15, p6 

    Reports on Aventis Inc.'s efforts to persuade the French government to drop its opposition to a possible merger with Novartis AG while setting another obstacle to the hostile bid by Sanofi-Synthelabo SA.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics